



Information on total number of voting rights and shares composing the share capital as at February 28, 2017

Paris, March 1st, 2017 : Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces the evolution of its share capital following the exercise of Founders' Share Warrant (BSPCE) and Share Warrant (BSA) and Free Shares (AGA).

The number of voting rights and shares composing its share capital as at February 28, 2017 is as follow:

Total voting rights	Total number of shares composing capital
Total real voting rights*: 13,181,370	13,206,757
Total Theoretical voting rights **: 13,206,757	

* The actual (or net) voting rights correspond to the total number of voting rights exercisable at General Meetings. They are calculated based on the total number of voting rights attached to the total number of shares, less any shares without voting rights (treasury shares, etc.)

**Theoretical (or gross) voting rights include all voting rights attached to the shares (including those without voting rights).

ABOUT PIXIUM VISION

Pixium Vision's Mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention as well as a rehabilitation period.

The company is developing two bionic retinal implant systems. IRIS®II, the company first bionic system, obtained CE mark in July 2016. In parallel, Pixium Vision has recently completed the pre-clinical study phases for PRIMA, a sub-retinal miniaturized wireless photovoltaic implant platform, and is planning to initiate first-in-human trials.

Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Hansen Experimental Physics Laboratory at Stanford University, and Moorfields Eye Hospital in London. The company is EN ISO 13485 certified.

For more information, please visit:  www.pixium-vision.com;
And follow us on:  @PixiumVision;  www.facebook.com/pixiumvision
 www.linkedin.com/company/pixium-vision



Pixium Vision is listed on Euronext (Compartment C) in Paris.

ISIN: FR0011950641; Mnemo: PIX

IRIS® is a trademark of Pixium-Vision SA

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Contacts

Pixium Vision

Didier Laurens, CFO

investors@pixium-vision.com

+33 1 76 21 47 68

MediaRelations : Newcap Media

Annie-Florence Loyer

afloyer@newcap.fr

+33 1 44 71 00 12 / +33 6 88 20 35 59

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).